More news from the National Cancer Research Institute (NCRI) Cancer Conference this week comes from researchers at the Institute of Cancer Research (ICR) in London. They’ve carried out a large-scale analysis of patient data from another trial to predict which men are most likely to experience unpleasant side effects after radiotherapy.
New research presented at the National Cancer Research Institute (NCRI) Cancer Conference shows men with naturally low levels of testosterone are less likely to develop prostate cancer. But the study has also raised some difficult questions.
Our new precision medicine research programme aims to tailor treatments based on the genetic make-up of a man’s prostate cancer. The results could extend the lives of more than 9,000 men with advanced disease every year in the UK.
Hayley Yarnley knows how much our new precision medicine research programme could have helped her father, Bernie, who died from advanced prostate cancer last December. She describes how the births of her children kept him going during his treatment, and why he was convinced scientists would one day find a cure.
In this guest blog Dr Chris Armstrong – Marcher, Mo grower and ambitious researcher – explains what he hopes to achieve with the Travelling Prize Fellowship we’ve just awarded him and how this critical leg up the academic research ladder will benefit men with prostate cancer.
Deciding whether 'to treat or not to treat' localised prostate cancer is one of the biggest dilemmas for men and their doctors. Now new research from one of our Centres of Excellence could help identify which cancers are likely to spread and which are harmless.
A type of radiotherapy that shapes radiation beams to tumors has grabbed headlines today. But more in-depth trials, already underway, are needed to give a clearer picture of the benefit for men.
The Duchess of Gloucester met with researchers and clinical triallists on a royal visit to our Belfast-Manchester Movember Centre of Excellence, where attempts to find new ways to tackle advanced prostate cancer are already showing exciting early results.
Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.
Courtney Pine, Gladstone Small and Paul Barber are the latest black celebrities to join our Stronger Knowing More campaign, after our worrying new poll raises fears of a fatal lack of awareness among doctors and patients about black men's higher risk of prostate cancer.